대화제약

067080KOSDAQ

42.5 / 100

Reference Date: 2026-10-23

Financial Score15.0 / 40

News Sentiment12.5 / 25

Momentum8.0 / 20

Disclosure7.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Declined 10.4% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Dae Hwa Pharmaceutical primarily engages in the manufacturing and sales of pharmaceuticals, medical devices, and raw materials, supplying a wide range of products such as antibiotics and pain relievers both domestically and internationally. The company has expanded its overseas markets through partnerships with German and Chinese firms and focuses on R&D investment for new drug development.

Number of Employees

369people

Average Salary

48.4M KRW

Score Calculation Basis

Detailed Financial Score

PER

106.38Industry Average 15.000.0Point

7.1x industry avg (risky)

PBR

2.35Industry Average 1.201.0Point

2.0x industry avg (risky)

ROE

3.00Industry Average 8.001.0Point

Well below industry avg

Debt Ratio

12.94Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20255.0 / 10 points

Revenue Growth Rate

1.0 / 3

Avg ▲0.7% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲94.5% (2-year basis)

ROE Trend

1.0 / 4

Avg ROE 1.1% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (13%, downtrend)

Current 10,000Won52-week high 23,30052-week low 7,870

1-month return1.0Point

1m -10.39% (falling)

Volume trend6.0Point

Volume surge

Detailed Disclosure

2 totalPositive 0Neutral 1Negative 1

Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-10-16
Negative불성실공시법인지정예고 (공시번복 1건, 공시불이행 1건)2026-10-12